Serial cardiac biomarkers for risk stratification of patients with COVID-19

Several studies have demonstrated an association between elevated cardiac biomarkers and adverse outcomes in patients with COVID-19. However, the prognostic and predictive capability of a multimarker panel in a prospectively collected, diverse “all-comers” COVID-19 population has not been fully eluc...

Full description

Saved in:
Bibliographic Details
Published in:Clinical biochemistry 2022-09, Vol.107, p.24-32
Main Authors: Tawiah, Kwaku, Jackson, Laurel, Omosule, Catherine, Ballman, Claire, Shahideh, Bobby, Scott, Mitchell G, Murtagh, Gillian, Farnsworth, Christopher W.
Format: Article
Language:English
Subjects:
Biomarkers
COVID-19
High sensitivity troponin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several studies have demonstrated an association between elevated cardiac biomarkers and adverse outcomes in patients with COVID-19. However, the prognostic and predictive capability of a multimarker panel in a prospectively collected, diverse “all-comers” COVID-19 population has not been fully elucidated. We prospectively assessed high sensitivity cardiac troponin I (hsTnI), NT-pro B-type Natriuretic Peptide (NT-proBNP), Galectin-3 (Gal-3), and procalcitonin (PCT) in 4,282 serial samples from 358 patients admitted with symptomatic, RT-PCR confirmed SARS-CoV-2 infection. Outcomes examined were 30-day in-hospital mortality and requirement for intubation within 10 days. Baseline hsTnI had the highest AUC for predicting 30-day mortality (0.81; 95% CI, 0.73–0.88), followed by NT-proBNP (0.80; 0.74–0.86), PCT (0.77; 0.70–0.84), and Gal-3 (0.68; 0.60–0.76). HsTnI 
ISSN:0009-9120
1873-2933
DOI:10.1016/j.clinbiochem.2022.06.002